Harbour BioMed HBM9378 Phase I data: does long-acting TSLP inhibition change asthma treatment economics?
Harbour BioMed’s HBM9378 Phase I data shows long half-life and safety. Find out what this means for asthma, COPD, and TSLP competition.
Can Regeneron Pharmaceuticals redefine allergy treatment with Phase 3 allergen-blocking antibodies and Dupilumab expansion
Find out how Regeneron Pharmaceuticals’ AAAAI 2026 data could reshape allergy treatment strategies and regulatory expectations.
GSK’s Exdensur wins FDA nod for severe asthma: Can twice-yearly dosing reset the biologics playbook?
GSK’s Exdensur has been approved by the FDA as the first biannual biologic for severe asthma. Find out what this means for patients, payers, and rivals.